CD32-CR T cells preferentially kill sensitive breast cancer (BC) cells, leading to their elimination in vitro and in vivo. CD32-CR-T cells at least mediate granule-dependent cytotoxicity, but this effect requires ICAM1 expression on target cells. The gene discussed is FCGR2C; the disease is breast carcinoma.